Company intelligence / Profile preview

Jinpai Chizhengtang Pharmaceutical

Ownership: Private
Development stage: Other

Overview

Jinpai Chizhengtang Pharmaceutical is a private Chinese pharmaceutical company focused on the development of herbal medicines for infectious and respiratory diseases. Its lead product, Qingfei Dayuan Granules, is in Phase 2 clinical trials for influenza. The company appears to have a narrow pipeline with one main clinical-stage asset and no disclosed advanced technology platforms or partnerships[1].

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Herbal medicineSmall molecule (inferred, as herbal medicines are composed of small molecules)
Industry: Biotech

Drug pipeline

1 asset

Qingfei Dayuan Granule

Beyond the preview

Go deeper on Jinpai Chizhengtang Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jinpai Chizhengtang Pharmaceutical.